Since the foundation, we have achieved continuous development that drives our economic growth , making us a leader in the production of oncology intermediates.
|
2007 |
Hunan Ouya is established. |
| 2008 |
Hunan Ouya signs a strategic cooperation agreement with the Chinese Academy of Sciences on the development of new anti-hepatitis B drugs. |
|
2009 |
The new anti-hepatitis B drugs won the "Science and Technology Innovation Award" in Hunan province. |
|
2010 |
The R&D center is established equipped with large-scale advanced instruments and equipment. |
| 2011 |
The company is awarded as the Hunan high-tech enterprise. |
| 2013 |
The new workshops with state-of-the- art facilities are completed. |
| 2017 | Entecavir which is a new anti-hepatitis B drug is succefully developed. |
| 2018 | The company expands to API segment. |
| 2020 |
Hunan Ouya finishes the registration of the first API Olmesartan Medoxomil |
| 2021 |
The Olmesartan Medoxomil is approved and active in CDE |
IPv6 network supported